Newsmeme!
Discover News you didn't know existed
Andromeda
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
SOUTHERN CROSS STARGAZER
Published July 4, 2009, 12:00 am, Miami Herald
SATURDAY In evening dusk, silver Saturn escorts Leo the Lion lower in the west and sets before midnight. Its edge-on rings reveal satellite moons. Saturn will be visible in the evening sky until August. Dim Ceres, largest asteroid, glides below the Lion's tail. Corvus the Crow leads Spica, in Virgo (Spring Maiden) into the southwest, followed by the stars of Libra. Huge Scorpius clears the ...
‘Action!’ in Manistee
Published July 3, 2009, 9:12 pm, Ludington Daily News
Filming of ‘What if...’
FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter
Published July 3, 2009, 5:07 am, Medical News Today
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease.
Sanofi-aventis' Multaq receives US FDA nod to treat patients with atrial fibrillation or atrial flutter
Published July 2, 2009, 10:48 pm, PharmaBiz
Sanofi-aventis announced that the US Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg tablets.
Sanofi-Aventis arrhythmia drug Multaq approved
Published July 2, 2009, 3:45 pm, INO News
(AP:TRENTON, N.J.) Sanofi-Aventis SA said Thursday its drug Multaq, which treats irregular heart rhythms, received marketing approval from the Food and Drug Administration, which turned it down three years ago.
Weekend activities at Guadalupe State Park
Published July 2, 2009, 9:42 am, SACommunties
The following programs are being offered at Guadalupe River State Park & Honey Creek State Natural Area this July Fourth weekend.
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Published July 2, 2009, 7:46 am, redOrbit
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets.
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Published July 2, 2009, 6:05 am, PR Newswire via Yahoo! Finance
Sanofi-aventis announced today that the U.S. Food and Drug Administration has approved Multaq® 400 mg Tablets. Patients with atrial fibrillation or atrial flutter soon will have a new treatment option to help improve current management of their disease.
A Publishing Flurry of Activity in the Science Fiction Department for Western Michigan University Physics Professor
Published July 2, 2009, 4:10 am, PR Newswire via Yahoo! Finance
Less than a year after garnering top honors in the global L. Ron Hubbard Writers of the Future Contest for new science fiction and fantasy writers, Allendale resident and writer Dr.
FDA Approves Multaq(R) for Patients With Atrial Fibrillation or Atrial Flutter
Published July 2, 2009, 1:26 am, FinanzNachrichten
Paris (ots/PRNewswire) - - Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |